|
Aug 4
|
AB Science announces the successful completion of a 2.55 million euros private placement
|
|
Jul 30
|
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
|
|
Jul 24
|
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
|
|
Jun 30
|
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
|
|
Jun 9
|
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
|